Biomea Fusion News

Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Repligen (RGEN) and Agenus (AGEN)

TipRanks07:42 ET

Barclays Sticks to Its Buy Rating for Biomea Fusion (BMEA)

TipRanks06:41 ET

Biomea Fusion GAAP EPS of -$1.09 Misses by $0.02

Seeking Alpha01:50 ET

Express News | Biomea Fusion Inc : JP Morgan Raises Target Price to $15 From $14

Reuters01:46 ET

Express News | Biomea Fusion Q1 EPS $(1.09) Misses $(0.91) Estimate

Benzinga17:12 ET

Biomea Fusion 1Q Loss/Shr $1.09 >BMEA

Biomea Fusion 1Q Loss/Shr $1.09 >BMEA

Dow Jones16:08 ET

Express News | Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights

Reuters16:05 ET

Press Release: Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights

Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights -- Reported positive data from the escalation portion of Phase 1/2 study (COVALENT-111) in type 2 diabetes

Dow Jones16:05 ET

DJT, BGFV and REAL Are Among After Hour Movers

Seeking AlphaApr 15 17:21 ET

Biomea Fusion Is Maintained at Outperform by Oppenheimer

Biomea Fusion Is Maintained at Outperform by Oppenheimer

Dow JonesApr 3 10:11 ET

Express News | Oppenheimer Maintains Outperform on Biomea Fusion, Maintains $70 Price Target

Moomoo 24/7Apr 3 10:01 ET

Biomea Fusion Drops as JPMorgan Downgrades on Data for Lead Asset

Seeking AlphaApr 2 13:18 ET

Express News | Biomea Fusion Shares Are Trading Lower After JP Morgan Downgraded the Stock From Overweight to Neutral and Lowered Its Price Target From $51 to $14

Moomoo 24/7Apr 2 10:54 ET

Biomea Fusion Cut to Neutral From Overweight by JP Morgan

Biomea Fusion Cut to Neutral From Overweight by JP Morgan

Dow JonesApr 2 10:32 ET

Express News | JP Morgan Downgrades Biomea Fusion to Neutral, Lowers Price Target to $14

Moomoo 24/7Apr 2 10:22 ET

Biomea Fusion Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/02/2024 3.74% JP Morgan $51 → $14 Downgrades Overweight → Neutral 04/01/2024 270.51% HC Wainwright & Co

BenzingaApr 2 10:20 ET

Biomea Fusion (BMEA) Receives a Buy From Scotiabank

TipRanksApr 2 07:15 ET

Analysts Offer Insights on Healthcare Companies: Humana (HUM), Baxter International (BAX) and Biomea Fusion (BMEA)

TipRanksApr 2 03:50 ET

Promising Efficacy of Biomea Fusion's BMF-219 in Type 1 Diabetes Treatment: A Positive Outlook on Early Clinical Data

TipRanksApr 1 20:45 ET

Biomea Fusion, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and devel

GlobeNewswireApr 1 16:10 ET